VETMEDIN COMPRIMÉS À CROQUER À 10 MG Comprimé (à mâcher)

Šalis: Kanada

kalba: prancūzų

Šaltinis: Health Canada

Veiklioji medžiaga:

Pimobendan

Prieinama:

BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC.

Dozė:

10MG

Vaisto forma:

Comprimé (à mâcher)

Sudėtis:

Pimobendan 10MG

Vartojimo būdas:

Orale

Vienetai pakuotėje:

50

Recepto tipas:

Prescription

Farmakoterapinė grupė:

Chiens

Produkto santrauka:

Numéro de groupe d'ingrédients actifs (GIA) :0149543004

Autorizacija statusas:

APPROUVÉ

Leidimo data:

2020-09-29

Pakuotės lapelis

VETMEDIN
® CHEWABLE TABLETS – 1.25 MG, 2.5 MG, 5.0 MG AND 10 MG
BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC. – CLEAN VERSION
BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC.
PAGE 1 OF 14
SUBMITTED AUGUST 27, 2020
1.25 MG, 2.5 MG, 5.0 MG AND 10 MG CARTONS - ENGLISH
FRONT (MAIN) PANEL:
DIN (02469480) (02469499) (02469502) (02469464)
PR
VETMEDIN
® (1.25 MG) (2.5 MG) (5.0 MG) (10 MG) CHEWABLE TABLETS
pimobendan chewable tablets
FOR VETERINARY USE ONLY
FOR DOGS
NET CONTENTS: 50 CHEWABLE TABLETS
(BI Logo on the bottom)
SIDE PANEL:
ACTIVE INGREDIENT: PIMOBENDAN (1.25 MG) (2.5 MG) (5.0 MG) (10 MG) PER
TABLET
See package insert for complete prescribing information.
INDICATIONS:
Dogs:
For the treatment of congestive heart failure originating from dilated
cardiomyopathy or valvular insufficiency. It is
recommended that the diagnosis of congestive heart failure be
confirmed by radiographs or diuretic responsiveness.
Treatment should be initiated only in symptomatic cases which will
benefit from increased myocardial contractility
(positive inotropy).
DOSAGE AND ADMINISTRATION
: Daily oral administration at a dose range of 0.2 mg to 0.6 mg
pimobendan/kg body
weight. The preferable daily dose is 0.5 mg/kg body weight. The dose
should be divided into two administrations at
approximately 12h intervals. Each dose should be given approximately
one hour before feeding. Vetmedin
®
chewable tablets may be combined with a diuretic treatment such as
furosemide in dogs with pulmonary edema
and/or ascites associated with congestive heart failure.
CAUTION
: Cardiac arrhythmias may indicate a more guarded prognosis. Dogs
should be monitored for presence of
arrhythmias during therapy. Appropriate anti-arrhythmic should be
initiated if indicated.
CONTRA-INDICATIONS:
Should not be used in cases of hypertrophic cardiomyopathies or
clinical conditions where an
augmentation of cardiac output is not possible for functional or
anatomical reasons (e.g. aortic stenosis).
WARNING: KEEP OUT OF REACH OF CHILDREN.
STORAGE:
Protect from moisture. S